Genomic association/linkage of sodium lithium countertransport in CEPH pedigrees

Hypertension

Volumn 40, Issue 5, 2002, Pages 619-628

  Schork, Nicholas J ^a   Gardner, Jeffrey P ^a   Zhang, Li ^a   Fallin, Danielle ^a   Thiel, Bonnie ^a   Jakubowski, Hieronim ^a   Aviv, Abraham ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Glutathione; Intermediate phenotype; Ion transport; Lymphocytes; Oxidative stress

Indexed keywords

LITHIUM; SODIUM;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR RISK; CELL IMMORTALIZATION; ENVIRONMENTAL FACTOR; ESSENTIAL HYPERTENSION; GENETIC ASSOCIATION; GENETIC LINKAGE; GLUTATHIONE METABOLISM; ION TRANSPORT; LYMPHOBLAST; NONHUMAN; OXIDATIVE STRESS; PEDIGREE; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ALLELES; ANGIOTENSINOGEN; ANTIPORTERS; CELL LINE, TRANSFORMED; CHROMOSOME MAPPING; ERYTHROCYTES; ETHYLMALEIMIDE; FEMALE; GENETIC MARKERS; GENOTYPE; GLUTATHIONE; HERPESVIRUS 4, HUMAN; HUMANS; ION TRANSPORT; LINKAGE (GENETICS); LITHIUM; LYMPHOCYTES; MALE; OXIDATIVE STRESS; PEDIGREE; PHENOTYPE; SULFHYDRYL COMPOUNDS;

EID: 0036842012     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000037131.41957.A8     Document Type: Article

References (51)

1. West IC, Rutherford PA, Thomas TH. Sodium-lithium countertransport: Physiology and function. J Hypertens. 1998;6:3-13.
2. Mead P, Wilkinson R, Thomas TH. Thiol protein defect in sodiumlithium countertransport in subset of essential hypertension. Hypertension. 1999:34:1275-1280.
3. + exchanger (NHE-1) in essential hypertension. Am J Hypertens. 1998;11:774-783.
4. + counter-transport. J Am Soc Nephrol. 1991;4:937-943.
5. + antiporter as a candidate gene in human essential hypertension. Hypertension. 1991;17:8-14.
6. + countertransport activity in hypertensive non-insulin-dependent diabetic patients: Role of insulin resistance and hypertensive treatment. Metabolism. 1997;46:1316-1323.
7. Ferri C, Bellini C, Desideri G, Valent M, De Mattia G, Santucci A, Hollenberg NK, Williams GH. Relationship between insulin resistance and nonmodulating hypertension: Link of metabolic abnormalities and cardiovascular risk. Diabetes. 1999;48:1623-1630.
8. Hunt SC, Williams RR, Smith JB, Ash KO. Associations of three erythrocyte cation transport systems with plasma lipids in Utah subjects. Hypertension. 1986;8:30-36.
9. Carr SJ, Thomas TH, Laker MF, and Wilkinson R. Elevated sodiumlithium countertransport: A familial marker of hyperlipidaemia and hypertension? J Hypertens. 1990;8:139-146.
10. Weder AB, Torretti BA, Julius S. Racial differences in erythrocyte cation transport. Hypertension. 1984;6:115-123.
11. Smith JB, Wade MB, Fineberg NS, Weinberger MH. Influence of race, sex, and blood pressure on erythrocyte sodium transport in humans. Hypertension. 1988;12:251-258.
12. Trevisan M, Ostrow D, Cooper RS, Sempos C, Stamler J. Sex and race differences in sodium-lithium countertransport and red cell sodium concentration. Am J Epidemiol. 1984;120:537-541.
13. Aviv A, Lasker N. Proposed deflects in membrane transport and intracellular ions as pathogenic factors in essential hypertension. In: Laragh JH, Brenner BM, eds. Hypertension, Pathophysiology, Diagnosis, and Management. New York: Raven Press; 1990:923-937.
14. Rebbeck TR, Turner ST, Michels VV. Moll PP. Genetic and environmental explanations for the distribution of sodium-lithium countertransport in pedigrees from Rochester, Minn. Am J Hum Genet. 1991;48:109-104.
15. Orlov SN, Pausova Z, Gossard F, Gaudet D, Tremblay J, Kotchen T, Cowley A, Larochelle P. Hamet P. Sibling resemblance in erythrocyte ion transporters in French-Canadian sibling pairs affected with essential hypertension. J Hypertens. 1999;17:1859-1865.
16. Cirillo M, Laurenzi M, Panarelli W, Trevisan M, Stamler J. Prospective analysis of traits related to 6-year change in sodium-lithium countertransport. Gubbio Popul Study Res Group Hypertens. 1999;33:887-893.
17. Broman KW, Murray JC, Sheffield VC, White RL, Weber JL. Comprehensive human genetic maps: Individual and sex-specific variation in recombination. Am J Hum Genet. 1998;63:861-869.
18. Xiong MM, Kruskall J, Boerwinkle E. TDT statistics for mapping quantitative trait loci. Ann Hum Genetics. 1998;62:431-452.
19. Good P. Permutation Tests. New York: Springer-Verlag; 1994.
20. Nickerson DA, Taylor SL, Weiss KM, Clark AG, Hutchinson RG, Stengard J, Salomaa V, Vartiainen E, Boerwinkle E, Sing CF. DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene. Nat Genetics. 1998;19:233-245.
21. Ardlie K, Liu-Cordero SN, Eberle MA, Daly M, Barrett J, Winchester E, Lander ES, Kruglyak L. Lower-than-expected linkage disequilibrium between tightly linked markers in humans suggests a role for gene conversion. Am J Hum Genetics. 2001;69:582-589.
22. Huttley GA, Smith MW, Carrington M, O'Brien SJ. A scan for linkage disequilibrium across the human genome. Genetics. 1998;152:1711-1722.
23. Statistical Analysis for Genetic Epidemiology. Cleveland, Ohio: Department of Epidemiology, and Biostatistics, Case Western Reserve University; 1996.
24. Lander ES, Kruglyak L. Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results. Nat Genetics. 1995;11:241-247.
25. + countertransport in human skin fibroblasts. Am J Physiol. 1997;272:C1373-C1379.
26. Spielman RS, Ewens WJ. The TDT and other family-based tests for linkage disequilibrium and association. Am J Hum Genetics. 1996:59:983-989.
27. Schweder T, Spjotvoll E. Plots of P-values to evaluate many tests simultaneously. Biometrika. 1982:69:493-502.
28. Webb G, Vaska V, Goggan M, Board P. Chromosomal localization of the gene for the human θ-class glutathione transferase (GSTT1). Genomics. 1996;33:121-123.
29. Coggan M, Whitbread L, Whittington A, Board P. Structure and organization of the human θ-class glutathione S-transferase and D-dopachrome tautomerase gene complex. Biochem J. 1998;334:617-623.
30. Kammerer CM, Cox LA, Mahaney MC, Royer J, Shadie RE. Sodium lithium countertransport activity is linked to chromosome 5 in the baboon. Hypertension. 2001;37:398-402.
31. Xu X, Rogus JJ, Terwedow HA, Yang J, Wang Z, Chen C, Niu T, Wang B, Xu H, Weiss S. Schork NJ, Fang Z. An extreme-sib-pair genome scan for genes regulating blood pressure. Am J Hum Genet. 1999;64:1694-1701.
32. Levy R, Livne A, Erythrocyte Li-Na countertransport system. Inhibition by N-ethylmaleimide probes for a conformational change of the transport system. Biochim Biophys Acta. 1984;777:157-166.
33. + countertransport kinetics by two types of thiol group. Biochim Biophys Acta. 1995;1235:317-322.
34. Rutherford PA, Thomas TH, O'Kelly J, West IC, Wilkinson R. Thiol group control of sodium-lithium countertransport kinetics in uraemia: Evidence of a membrane abnormality affected by haemodialysis. Nephron. 1996;72:184-188.
35. Thomas TH, Rutherford PA, West IC, Wilkinson R. Sulfhydryl group control of sodium-lithium countertransport kinetics: A membrane protein control abnormality in essential hypertension. Eur J Clin Invest. 1995;25:235-240.
36. Watkins SL, West IC, Wilkinson R, Thomas TH. Abnormal thiol reactivity of tropomyosin in essential hypertension and its association with abnormal sodium-lithium countertransport kinetics. J Hypertens. 2001;19:485-493.
37. Jakoby WB, Ziegler DM. The enzymes of detoxication. J Biol Chem. 2001;265:20715-20718.
38. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology. 2000;61:154-166.
39. Lacy F, Kailasam MT, O'Connor DT, Schmid-Schonbein GW, Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: Role of heredity, gender, and ethnicity. Hypertension. 2000;36:878-884.
40. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
41. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension. 2000;37:1047-1052.
42. Lacy F, O'Connor DT, Schmid-Schonbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens. 1998;16:291-303.
43. Vaziri ND, Ni Z, Oveisi F, Tmavsky-Hobbs DL. Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension. 2000;36:957-964.
44. Wu L, Juurlink BH. The impaired glutathione system and its up-regulation by sulforaphane in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens. 2001;19:1819-1825.
45. Vaziri ND, Wang XQ, Oveisi F, Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension. 2000;36:142-146.
46. Suzuki H, Swei A, Zweifach BW, Schmid-Schonbein GW. In vivo evidence for microvascular oxidative stress in spontaneously hypertensive rats: Hydroethidine microfluorography. Hypertension. 1995;25:1083-1089.
47. Ortiz MC, Manriquez MC, Romero JC, Juncos LA. Antioxidants block angiotensin II-induced increases in blood pressure and endothelin. Hypertension. 2001;38(3 pt 2):655-659.
48. Morrison JA, Jacobsen DW, Sprecher DL, Robsinson K, Khoury P, Daniels SR. Serum glutathione in adolescent males predicts parental coronary heart disease. Circulation. 1999;100:2244-2247.
49. Gu M, Love H, Schofield D, Turkie W, Odom H, Braganza JM. A pilot study of blood antioxidant and free radical marker profiles in patients awaiting coronary artery bypass grafting. Clin Chim Acta. 1996;252:182-195.
50. Bridges AB, Scott NA, Pringle TH, McNeill GP, Belch JJ. Relationship between the extent of coronary artery disease and indicators of free radical activity. Clin Cardiol. 1992;15:169-174.
51. phox in lymphoblast cell lines. J Hypertens. 2002;20:677-683.